Xylem celebrates World Water Day across the globe with launch of month-long employee volunteer challenge

Xylem’s ‘Make Your Mark 30-Day Challenge’ aims to highlight the importance of water and environmental issues through water-related community activities RYE BROOK, N.Y.–(BUSINESS WIRE)–Mar. 22, 2017– In celebration of World Water Day, Xylem Inc. (NYSE:XYL) is launching a month-long volunteer challenge for Xylem colleagues across the globe to highlight the importance of water and environmental... Read more

Fabric Genomics and Sentieon Sign Strategic Partnership to Bring Advanced Genomic Analysis Capabilities to the Clinical Market

Technology Collaboration to Power Fabric StandardTM, the Fastest and Most Accurate Secondary Analysis Solution Available March 21, 2017 06:00 AM Pacific Daylight Time OAKLAND, Calif. & MOUNTAIN VIEW, Calif. & PHOENIX–(BUSINESS WIRE)–Fabric Genomics, a global computational genomics company, and Sentieon, which develops highly optimized algorithms for bioinformatics applications, today announced a technology partnership that will enhance... Read more

Kailos Genetics Announces Co-marketing Agreement with Illumina, Inc. for Pharmacogenetics Solution for Research

Agreement expands Kailos’ use of market-leading next-generation sequencing solutions March 21, 2017 06:00 AM Pacific Daylight Time HUNTSVILLE, Ala.–(BUSINESS WIRE)–Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced it has entered into a co-marketing agreement with Illumina, Inc. (NASDAQ: ILMN). Under the terms of the... Read more

Agilent Technologies Enhances Exome Sequencing for Clinical Research

New Target Enrichment Product Delivers Deep Coverage of Disease Relevant Content SANTA CLARA, Calif., March 21, 2017 Agilent Technologies Inc. (NYSE: A) today introduced a new target enrichment solution for next-generation DNA sequencing. Agilent SureSelect Clinical Research Exome V2 delivers more than 1,000 additional, disease relevant targets compared to the company’s earlier version of the... Read more